Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Puretech Health Plc ADR
(NQ:
PRTC
)
28.50
+1.02 (+3.71%)
Streaming Delayed Price
Updated: 2:07 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Puretech Health Plc ADR
< Previous
1
2
3
4
5
Next >
PureTech Announces Annual Results for Year Ended December 31, 2023
April 25, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Results
April 18, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
April 16, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
April 11, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
April 09, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Proposes $100 Million Capital Return
March 19, 2024
From
PureTech Health plc
Via
Business Wire
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
March 18, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
March 13, 2024
From
PureTech Health plc
Via
Business Wire
PureTech to Present at Two Upcoming Investor Conferences
February 27, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
February 27, 2024
From
PureTech Health plc
Via
Business Wire
PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
December 22, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Year End Update and Outlook for 2024
December 20, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
December 07, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
November 29, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
November 17, 2023
From
PureTech Health plc
Via
Business Wire
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
November 14, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Present at Two Upcoming Investor Conferences
October 17, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
October 11, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
October 04, 2023
From
PureTech Health plc
Via
Business Wire
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
September 28, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
September 27, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Health plc – Half-Year Report
August 29, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Half-Yearly Results
August 22, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
August 01, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
June 21, 2023
From
PureTech Health plc
Via
Business Wire
Results of PureTech's Annual General Meeting
June 13, 2023
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the Jefferies Healthcare Conference
May 24, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
May 09, 2023
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
May 04, 2023
From
PureTech Health plc
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.